← The SEC Ephemeris: the whole map
Aldeyra Therapeutics reproxalap
In the graph: all 46 documents (303 pages).
- Application
- NDA 216442
- Ticker
- ALDX
- Product
- reproxalap
- Disease area
- Dry eye disease
- Response path
- Resubmitted; CRL again
- Complete Response Letters
- March 16, 2026 · April 2, 2025
- Where it stands
- Three CRLs (2023, 2025, 2026), efficacy insufficiency each time. Deciding: appeal, new trial or abandon.
Also in ophthalmology: Outlook Therapeutics
From FDA letters and SEC filings. Not investment or medical advice.